JP2014523444A - 癌の炎症性環境に基づいて治療用積載物を放出する、腹腔内投与されるナノ担体 - Google Patents

癌の炎症性環境に基づいて治療用積載物を放出する、腹腔内投与されるナノ担体 Download PDF

Info

Publication number
JP2014523444A
JP2014523444A JP2014521722A JP2014521722A JP2014523444A JP 2014523444 A JP2014523444 A JP 2014523444A JP 2014521722 A JP2014521722 A JP 2014521722A JP 2014521722 A JP2014521722 A JP 2014521722A JP 2014523444 A JP2014523444 A JP 2014523444A
Authority
JP
Japan
Prior art keywords
nanocarrier
nanocarrier composition
nanoparticles
group
lipid bilayer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014521722A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523444A5 (https=
Inventor
リーマ ゼイネルデン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNM Rainforest Innovations
Original Assignee
STC UNM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STC UNM filed Critical STC UNM
Publication of JP2014523444A publication Critical patent/JP2014523444A/ja
Publication of JP2014523444A5 publication Critical patent/JP2014523444A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y10S977/911—Cancer cell destruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014521722A 2011-07-19 2012-07-18 癌の炎症性環境に基づいて治療用積載物を放出する、腹腔内投与されるナノ担体 Pending JP2014523444A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509251P 2011-07-19 2011-07-19
US61/509,251 2011-07-19
PCT/US2012/047133 WO2013012891A1 (en) 2011-07-19 2012-07-18 Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers

Publications (2)

Publication Number Publication Date
JP2014523444A true JP2014523444A (ja) 2014-09-11
JP2014523444A5 JP2014523444A5 (https=) 2015-09-10

Family

ID=47558435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014521722A Pending JP2014523444A (ja) 2011-07-19 2012-07-18 癌の炎症性環境に基づいて治療用積載物を放出する、腹腔内投与されるナノ担体

Country Status (9)

Country Link
US (1) US9532949B2 (https=)
EP (1) EP2734191A4 (https=)
JP (1) JP2014523444A (https=)
CN (1) CN103917224A (https=)
AU (1) AU2012284147A1 (https=)
BR (1) BR112014001346A8 (https=)
CA (1) CA2842306A1 (https=)
EA (1) EA201490302A1 (https=)
WO (1) WO2013012891A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018016645A1 (ja) * 2016-07-22 2018-01-25 国立大学法人秋田大学 新規リン脂質およびその利用ならびにリン脂質分離測定法の開発
JP2018505224A (ja) * 2015-02-13 2018-02-22 オーピーナノ シーオー エルティーディーＯＰ Ｎａｎｏ Ｃｏ．，Ｌｔｄ． ナノ粒子を含む組成物並びに腫瘍を治療する方法
JP2019531342A (ja) * 2016-09-13 2019-10-31 ラスナ・リサーチ・インコーポレイテッド ダクチノマイシン組成物並びに骨髄異形成症候群及び急性骨髄性白血病の治療方法

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993437B2 (en) 2007-12-06 2018-06-12 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications
ES2593027T3 (es) 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Composición liposomal
US8992984B1 (en) 2009-10-21 2015-03-31 Stc.Unm Protocells and their use for targeted delivery of multicomponent cargos to cancer cells
US20120207795A1 (en) 2010-07-13 2012-08-16 The Regents Of The University Of California Cationic polymer coated mesoporous silica nanoparticles and uses thereof
AU2012249474A1 (en) 2011-04-28 2013-11-07 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
US10220004B2 (en) 2011-07-14 2019-03-05 The Regents Of The University Of California Method of controlled delivery using sub-micron-scale machines
BR112014001346A8 (pt) 2011-07-19 2018-05-08 Stc Unm composto nanotransportador, método, composto farmacêutico e uso de um composto
US9687569B2 (en) 2012-08-16 2017-06-27 University Of Washington Through Its Center For Commercialization Theranostic nanoparticle and methods for making and using the nanoparticle
EP4378461A3 (en) * 2013-03-05 2024-09-11 The Regents of University of California Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents
CN103611172B (zh) * 2013-12-02 2015-06-03 东南大学 载纳米雄黄磁性白蛋白纳米球及制备方法
CN103919803B (zh) * 2014-04-16 2018-07-31 厦门大学 一种装载砷剂的抗癌纳米药物及其制备方法
WO2016044716A1 (en) * 2014-09-19 2016-03-24 The American University In Cairo Nanoparticle-based combinatorial therapy
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
JP2018530623A (ja) * 2015-10-15 2018-10-18 リポメディックス・ファーマシューティカルズ・リミテッドＬｉｐｏｍｅｄｉｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． ドキソルビシンおよびマイトマイシンｃプロドラッグを共封入したリポソーム組成物
US20180369422A1 (en) * 2015-12-31 2018-12-27 City Of Hope Nanoparticles for cancer detection
US11672866B2 (en) 2016-01-08 2023-06-13 Paul N. DURFEE Osteotropic nanoparticles for prevention or treatment of bone metastases
CN108601746B (zh) 2016-01-08 2024-09-13 加利福尼亚大学董事会 用于运载物递送的具有脂质双层包衣的中孔二氧化硅纳米颗粒
US12029724B2 (en) * 2016-04-28 2024-07-09 Eisai R&D Management Co., Ltd. Method for inhibiting tumor growth
CN107362142B (zh) * 2016-05-13 2023-04-25 山东新时代药业有限公司 一种氟维司群脂质体注射液及其制备方法
CN106943378B (zh) * 2017-02-16 2020-09-15 上海交通大学 红细胞膜包封聚酯类载三氧化二砷纳米粒及其制备方法
WO2018160865A1 (en) 2017-03-01 2018-09-07 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
CN107096037B (zh) * 2017-04-11 2019-12-31 同济大学 一种酶促小分子自组装制备纳米凝胶的方法
CN107213479B (zh) * 2017-06-22 2018-12-28 苏州杰纳生物科技有限公司 一种包含过氧化氢酶的组合物及用途
CN108014094A (zh) * 2017-12-26 2018-05-11 厦门大学 一种含顺铂和砷剂的纳米药物及其制备方法
US12383499B2 (en) 2018-01-01 2025-08-12 The Regents Of The University Of California Scale up synthesis of silicasome nanocarriers
WO2019213270A1 (en) * 2018-05-01 2019-11-07 Rutgers, The State University Of New Jersey Benzalkonium-embedded mesostructured silica compositions and uses of same
WO2020068798A1 (en) 2018-09-24 2020-04-02 Guo Jimin Living mammalian cells modified with functional modular nanoparticles
MX2021005110A (es) * 2018-11-02 2021-08-24 Tesorx Pharma Llc Quimioterapia intraperitoneal mejorada con liposomas.
TR201820952A2 (tr) * 2018-12-28 2020-07-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Granülosi̇t koloni̇ uyarici faktör i̇çeren bi̇r kombi̇nasyon
US12208164B2 (en) 2019-02-28 2025-01-28 Unm Rainforest Innovations Modular metal-organic polyhedra superassembly compositions
US11207348B2 (en) 2019-04-25 2021-12-28 Imam Abdulrahman Bin Faisal University Spinel ferrite impregnated mesoporous silica containing a platinum complex
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CN110448541B (zh) * 2019-08-02 2021-10-01 中山大学 双功能化纳米粒、可溶性微针及其制备方法与应用
CN114686416B (zh) * 2020-12-30 2024-03-19 湖南大学 一种膜融合脂质体及其应用
US11779652B2 (en) 2021-06-18 2023-10-10 Imam Abdulrahman Bin Faisal University Porous silicate/magnetic ferrite nanocarrier for combination anti-cancer therapeutic and antioxidant delivery
CN114031048B (zh) * 2021-11-09 2024-03-15 广州天科生物科技有限公司 一种纳米硒的制备方法
CN115089728B (zh) * 2022-06-16 2024-01-26 磐如生物科技(天津)有限公司 一种膀胱癌靶向纳米药物及其制备方法
CN115105584B (zh) * 2022-06-28 2023-03-31 长春生物制品研究所有限责任公司 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07502261A (ja) * 1991-09-09 1995-03-09 トンプソン　デビッド　エイチ 光活性化可能なトリガーされた放出を伴なうリポソーマル送達システム
US20080279764A1 (en) * 2007-03-09 2008-11-13 Anthony Manganaro Method and composition for treating cancer
JP2010500340A (ja) * 2006-08-11 2010-01-07 パナセア バイオテック リミテッド 活性成分を送達するための粒子、その製造方法、および組成物
WO2010078569A2 (en) * 2009-01-05 2010-07-08 Stc.Unm Porous nanoparticle supported lipid bilayer nanostructures
JP2011500520A (ja) * 2007-10-12 2011-01-06 ノヴォソム アクチェンゲゼルシャフト 中性脂質を含有する両性リポソームの改良または該両性リポソームに関連する改良

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820879A (en) * 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
ATE209887T1 (de) * 1993-04-02 2001-12-15 Anticancer Inc Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6264741B1 (en) 1998-11-25 2001-07-24 Sandia Corporation Self-assembly of nanocomposite materials
US6350464B1 (en) * 1999-01-11 2002-02-26 Guilford Pharmaceuticals, Inc. Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
WO2003016040A1 (en) 2001-04-16 2003-02-27 The Regents Of The University Of California Membrane mimetic architectures on nanoporous materials
US20060177495A1 (en) 2001-12-21 2006-08-10 Christine Allen Polymer-lipid delivery vehicles
US20040005352A1 (en) 2002-04-16 2004-01-08 Lopez Gabriel P. Biologically functionalized porous microspheres
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
US7563451B2 (en) 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
US20070037751A1 (en) * 2003-08-06 2007-02-15 Gastrotech Pharma A/S Uses of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
KR20070110084A (ko) 2005-02-14 2007-11-15 오스트레일리언뉴클리어사이언스앤드테크놀로지오거나이제이션 층상 나노입자
US7514267B1 (en) 2005-08-19 2009-04-07 Stcunm Detection systems utilizing supported lipid bilayers
US20080160313A1 (en) 2006-04-26 2008-07-03 Gabriel Lopez Lipid bilayers on nanotextured solid surfaces
EP2099496A2 (en) 2006-12-08 2009-09-16 Massachusetts Institute of Technology Delivery of nanoparticles and/or agents to cells
US9993437B2 (en) 2007-12-06 2018-06-12 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications
US20110105995A1 (en) * 2008-01-16 2011-05-05 Zhu Ting F Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
US8962344B2 (en) 2008-03-16 2015-02-24 Synamem Corporation Membrane-coated particles
CA2722183C (en) 2008-04-25 2018-09-18 Northwestern University Nanostructures suitable for sequestering cholesterol and other molecules
JP5366612B2 (ja) 2008-05-20 2013-12-11 株式会社東芝 画像処理装置、画像処理方法および画像処理プログラム
CN101658533A (zh) 2008-08-29 2010-03-03 首都医科大学宣武医院 抗肿瘤药物的干细胞递送
US8992984B1 (en) 2009-10-21 2015-03-31 Stc.Unm Protocells and their use for targeted delivery of multicomponent cargos to cancer cells
US20130017210A1 (en) 2010-03-17 2013-01-17 Stc.Unm Display of antibody fragments on virus-like particles of rna bacteriophages
US20110300186A1 (en) 2010-04-14 2011-12-08 Battelle Memorial Institute Functionalized Nano- and Micro-materials for Medical Therapies
AU2012249474A1 (en) 2011-04-28 2013-11-07 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
BR112014001346A8 (pt) 2011-07-19 2018-05-08 Stc Unm composto nanotransportador, método, composto farmacêutico e uso de um composto
JP2014532071A (ja) 2011-10-14 2014-12-04 エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ カーゴの経皮送達を含む標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその方法
WO2013103614A1 (en) 2011-12-30 2013-07-11 Stc.Unm Crlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all)
US20160151482A1 (en) 2013-04-02 2016-06-02 Stc. Unm Mesoporous alum nanoparticles as a universal platform for antigen adsorption, presentation, and delivery
WO2014165608A1 (en) 2013-04-02 2014-10-09 Stc. Unm Antibiotic protocells and related pharmaceutical formulations and methods of treatment
EP3046543A1 (en) 2013-09-18 2016-07-27 Stc.Unm Torroidal mesoporous silica nanoparticles (tmsnps) and related protocells
WO2015042268A1 (en) 2013-09-18 2015-03-26 Stc.Unm Core and surface modification of mesoporous silica nanoparticles to achieve cell specific targeting in vivo

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07502261A (ja) * 1991-09-09 1995-03-09 トンプソン　デビッド　エイチ 光活性化可能なトリガーされた放出を伴なうリポソーマル送達システム
JP2010500340A (ja) * 2006-08-11 2010-01-07 パナセア バイオテック リミテッド 活性成分を送達するための粒子、その製造方法、および組成物
US20080279764A1 (en) * 2007-03-09 2008-11-13 Anthony Manganaro Method and composition for treating cancer
JP2011500520A (ja) * 2007-10-12 2011-01-06 ノヴォソム アクチェンゲゼルシャフト 中性脂質を含有する両性リポソームの改良または該両性リポソームに関連する改良
WO2010078569A2 (en) * 2009-01-05 2010-07-08 Stc.Unm Porous nanoparticle supported lipid bilayer nanostructures

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. AM. CHEM. SOC., vol. 131, JPN6016016419, 2009, pages 7567 - 7569, ISSN: 0003308874 *
NAT. MATER., vol. 10, JPN6016016420, April 2011 (2011-04-01), pages 389 - 397, ISSN: 0003308875 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018505224A (ja) * 2015-02-13 2018-02-22 オーピーナノ シーオー エルティーディーＯＰ Ｎａｎｏ Ｃｏ．，Ｌｔｄ． ナノ粒子を含む組成物並びに腫瘍を治療する方法
WO2018016645A1 (ja) * 2016-07-22 2018-01-25 国立大学法人秋田大学 新規リン脂質およびその利用ならびにリン脂質分離測定法の開発
JPWO2018016645A1 (ja) * 2016-07-22 2019-06-13 国立大学法人秋田大学 新規リン脂質およびその利用ならびにリン脂質分離測定法の開発
JP2022118008A (ja) * 2016-07-22 2022-08-12 株式会社リピドームラボ 新規リン脂質およびその利用ならびにリン脂質分離測定法の開発
JP2019531342A (ja) * 2016-09-13 2019-10-31 ラスナ・リサーチ・インコーポレイテッド ダクチノマイシン組成物並びに骨髄異形成症候群及び急性骨髄性白血病の治療方法
JP7032406B2 (ja) 2016-09-13 2022-03-08 ラスナ・リサーチ・インコーポレイテッド ダクチノマイシン組成物並びに骨髄異形成症候群及び急性骨髄性白血病の治療方法

Also Published As

Publication number Publication date
CA2842306A1 (en) 2013-01-24
EP2734191A1 (en) 2014-05-28
US9532949B2 (en) 2017-01-03
EA201490302A1 (ru) 2014-07-30
CN103917224A (zh) 2014-07-09
BR112014001346A2 (pt) 2017-07-18
WO2013012891A1 (en) 2013-01-24
US20140212479A1 (en) 2014-07-31
BR112014001346A8 (pt) 2018-05-08
EP2734191A4 (en) 2015-04-29
AU2012284147A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
US9532949B2 (en) Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
Zhang et al. Gemcitabine nanoparticles promote antitumor immunity against melanoma
Kong et al. Biodegradable hollow mesoporous silica nanoparticles for regulating tumor microenvironment and enhancing antitumor efficiency
CA2865279C (en) Nanostructures for treating cancers and other conditions
ES2819059T3 (es) Liposomas que encapsulan conjuntamente un bifosfonato y un agente anfipático
WO2021076630A1 (en) Nano-enabled immunotherapy in cancer
JP2012529501A (ja) ホスファチジルエタノールアミンを含む音響感受性薬物送達粒子
US20250313531A1 (en) Formulated and/or Co-Formulated Liposome Compositions Containing IDO Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof
JP2023507322A (ja) がんの処置において有用なＴｏｌｌ様受容体（「ＴＬＲ」）アゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法
WO2015178343A1 (ja) ｓｉＲＮＡ細胞内送達のための脂質膜構造体
Gajera et al. An overview of FDA approved liposome formulations for cancer therapy
NAYEK et al. Recent nanocochleate drug delivery system for cancer treatment: a review
JP2012529502A (ja) 非ラメラ形成ホスファチジルコリンを含む音響感受性薬物送達粒子
JPWO2005087196A1 (ja) 免疫応答システムを利用したドラッグデリバリーシステム
JPWO2005021012A1 (ja) ゲムシタビン封入薬剤担体
JP2023514324A (ja) がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法
WO2023091168A1 (en) Formulated and/or co-formulated nanocarriers compositions containing immunogenic cell death (icd) inducing prodrugs useful in the treatment of cancer and methods thereof
US10925831B2 (en) Liposomal formulations of platinum-acridine anticancer agents and methods thereof
US12478690B2 (en) Methods and systems for controlled release of drug cargo via ATP-responsive liposomes
JP2024510613A (ja) がんの処置に有用なＡ２ａＲアンタゴニストプロドラッグを含有する製剤化および／または共製剤化されたリポソーム組成物ならびにその方法
Stras Environmentally Responsive Liposomes for Treatment of Metastatic Triple Negative Breast Cancer
EP4211144A1 (en) Formulated and/or co-formulated liposome compositions containing pd-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
Rebelo Development of Liposomal Formulations for Drug Delivery to Breast Cancer Cells

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150717

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160629

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170123